Survival of patients with clinical stage IIIA non–small cell lung cancer after induction therapy: Age, mediastinal downstaging, and extent of pulmonary resection as independent predictors

Background In clinical stage IIIA non–small cell lung cancer, the role of surgical resection, particularly pneumonectomy, after induction therapy remains controversial. Our objective was to determine factors predictive of survival after postinduction surgical resection. Methods We retrospectively re...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of thoracic and cardiovascular surgery 2011, Vol.141 (1), p.48-58
Hauptverfasser: Paul, Subroto, MD, Mirza, Farooq, MD, Port, Jeffrey L., MD, Lee, Paul C., MD, Stiles, Brendon M., MD, Kansler, Amanda L., MPH, Altorki, Nasser K., MD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background In clinical stage IIIA non–small cell lung cancer, the role of surgical resection, particularly pneumonectomy, after induction therapy remains controversial. Our objective was to determine factors predictive of survival after postinduction surgical resection. Methods We retrospectively reviewed a prospectively collected database of 136 patients who underwent surgical resection after induction chemotherapy (n = 119) or chemoradiation (n = 17) from June 1990 to January 2010. Results One hundred five lobectomies or bilobectomies and 31 pneumonectomies were performed. There was 1 perioperative death (pneumonectomy). Seventy-one patients had downstaging to N0 or N1 nodal status (52%). There were 2 complete pathologic responses. Median follow-up was 42 months (range, 0.69–136 months). Overall 5-year survival for entire cohort was 33% (36% lobectomy, 22% pneumonectomy, P  = .001). Patients with pathologic downstaging to pN0 or pN1 had improved 5-year survival (45% vs 20%, P  = .003). For patients with pN0 or pN1 disease, survival after lobectomy was better than after pneumonectomy (48% vs 27%, P  = .011). In patients with residual N2 disease, there was no statistically significant survival difference between lobectomy and pneumonectomy (5-year survival, 21% vs 19%; P  = .136). Multivariate analysis showed as independent predictors of survival age (hazard ratio, 1.05; P  = .002), extent of resection (hazard ratio, 2.01; P  = .026), and presence of residual pN2 (hazard ratio, 1.60; P  = .047). Conclusions After induction therapy for patients with clinical stage IIIA disease, both pneumonectomy and lobectomy can be safely performed. Although survival after lobectomy is better, long-term survival can be accomplished after pneumonectomy for appropriately selected patients. Nodal downstaging is important determinant of survival, particularly after lobectomy.
ISSN:0022-5223
1097-685X
DOI:10.1016/j.jtcvs.2010.07.092